This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver | MicrobiomeTrials
← Back to trials NCT07364474
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-01-27Est. Completion: 2027-12
Enrollment target: 20 participantsLocations Massachusetts General Hospital, Boston, Massachusetts, United States Other microbiome trials you might be interested in Choroidal Melanoma Indeterminate Lesions Uveal Melanoma Ocular Melanoma
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 cli…
East Melbourne, Australia Est. completion Aug 15, 2028
Ciliary Body and Choroid Melanoma, Medium/Large Size Ciliary Body and Choroid Melanoma, Small Size Iris Melanoma Stage I Intraocular Melanoma Stage IIA Intraocular Melanoma
Stage IIB Intraocular Melanoma
Stage IIIA Intraocular Melanoma
Stage IIIB Intraocular Melanoma
Stage IIIC Intraocular Melanoma
Stage I Uveal Melanoma AJCC V7
Stage II Uveal Melanoma AJCC V7
Stage III Uveal Melanoma AJCC V7
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (e…
Philadelphia, United States Est. completion Dec 31, 2027